To the Editor:Chronic thromboembolic pulmonary hypertension(CTEPH)is a chronic progressive disease in which pulmonary artery pressure(PAP)increases and eventually leads to right heart failure and death.Balloon pulmona...To the Editor:Chronic thromboembolic pulmonary hypertension(CTEPH)is a chronic progressive disease in which pulmonary artery pressure(PAP)increases and eventually leads to right heart failure and death.Balloon pulmonary angioplasty(BPA)is a new and effective treatment for CTEPH patients who are unsuitable for surgery or who develop recurrent or persistent pulmonary hypertension after pulmonary endarterectomy(PEA).In recent years,major medical centers at home and abroad have been gradually developing and improving BPA,but overall,a unified treatment process and complication control strategy is lacking.展开更多
基金Natural Science Foundation of Guangdong Province(No.2021A1515011373)
文摘To the Editor:Chronic thromboembolic pulmonary hypertension(CTEPH)is a chronic progressive disease in which pulmonary artery pressure(PAP)increases and eventually leads to right heart failure and death.Balloon pulmonary angioplasty(BPA)is a new and effective treatment for CTEPH patients who are unsuitable for surgery or who develop recurrent or persistent pulmonary hypertension after pulmonary endarterectomy(PEA).In recent years,major medical centers at home and abroad have been gradually developing and improving BPA,but overall,a unified treatment process and complication control strategy is lacking.